Cystic Fibrosis

Take this brief test to find out what you know about key developments in the evolution of this emerging treatment option.

Risk factors that may help identify CF patients vulnerable to gaps in care include younger age, insurance status, and geographic change.

Two first-in-class migraine drugs, the first generic version of NuvaRing®, and 7 more fourth quarter FDA-approved drugs for primary care.

For people with CF, their caregivers, loved ones, and clinicians, click through summaries of 10 well-established sources of support for all aspects of the condition.

The burden of poor mental health among CF patients is significant and impacts all aspects of disease management. Test yourself on international best practices for screening and treatment. 

Depression in people with cystic fibrosis is 2 times higher than in the general population and among their caretakers, 3 times higher. The toll on treatment adherence is significant.

Cystic fibrosis medication adherence rates at Fairview Health Services in Minneapolis are 70% higher than at retail pharmacies. Patient Care found out why. Interview, here.

Trikafta™ is the first triple combination therapy approved for the treatment of the most common cystic fibrosis mutation. 

Rates of adherence to cystic fibrosis treatment plans have been reported as low as 36%. The motivational interviewing approach could help, according to MI trainer Ellen R. Glovsky, PhD, RD, LDN.

Motivational interviewing uses the common human problem of ambivalence about change to help clients shape their own solutions.

Cystic fibrosis treatment guidelines must evolve to keep pace with new treatments and disease knowledge. Try 7 questions on the latest iteration.

Pilot study success with a new cystic fibrosis treatment adherence tool may augur similar positive results from current RCT. Outcomes are due, soon.